AN2 Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
ANTX$4.33+8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $15,647 | $27,219 |
| Short-term investments | 91,648 | 68,840 |
| Prepaid expenses and other current assets | 3,212 | 2,509 |
| Right-of-use asset, net | — | 53 |
| Total current assets | 110,507 | 98,621 |
| Long-term investments | 27,194 | 3,219 |
| Other assets, long-term | 1,043 | 720 |
| Total assets | $138,744 | $102,560 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,676 | $2,122 |
| Accrued compensation | 4,018 | 2,168 |
| Accrued liabilities | 6,681 | 2,837 |
| Other current liabilities | 666 | — |
| Operating lease liabilities | — | 53 |
| Options subject to repurchase, short-term | 2 | 6 |
| Total current liabilities | 14,043 | 7,186 |
| Options subject to repurchase, long-term | — | 2 |
| Total liabilities | 14,043 | 7,188 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2023 and 2022; 29,741,445 and 19,402,658 shares issued and outstanding at December 31, 2023 and 2022, respectively | — | — |
| Additional paid-in capital | 278,881 | 185,469 |
| Accumulated other comprehensive gain (loss) | 275 | (374) |
| Accumulated deficit | (154,455) | (89,723) |
| Total stockholders’ equity | 124,701 | 95,372 |
| Total liabilities and stockholders’ equity | $138,744 | $102,560 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.